Last update 20 Mar 2025

Ziltivekimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
COR 001, COR-001
Target
Action
inhibitors
Mechanism
IL-6 inhibitors(Interleukin-6 inhibitors)
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute myocardial infarctionPhase 3
United States
25 Jun 2024
Acute myocardial infarctionPhase 3
China
25 Jun 2024
Acute myocardial infarctionPhase 3
Japan
25 Jun 2024
Acute myocardial infarctionPhase 3
Argentina
25 Jun 2024
Acute myocardial infarctionPhase 3
Australia
25 Jun 2024
Acute myocardial infarctionPhase 3
Brazil
25 Jun 2024
Acute myocardial infarctionPhase 3
Bulgaria
25 Jun 2024
Acute myocardial infarctionPhase 3
Canada
25 Jun 2024
Acute myocardial infarctionPhase 3
Czechia
25 Jun 2024
Acute myocardial infarctionPhase 3
Denmark
25 Jun 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Inflammation | Chronic Kidney Diseases
C-reactive Protein Expression
261
nlzhhoubht(qtwknnflld) = eurakefurd awwdfpqhdn (cztflqridr )
Positive
01 Jan 2024
nlzhhoubht(qtwknnflld) = cxpcrzegxz awwdfpqhdn (cztflqridr )
Phase 2
264
(Placebo)
xrqyinwflt(sayrlfifjv) = zxybeqrmzx xtxtniowpm (bqeucywayx, rspyprtibp - cuaciuigmq)
-
09 Aug 2023
(Ziltivekimab 7.5 mg)
xrqyinwflt(sayrlfifjv) = ukfnutlmic xtxtniowpm (bqeucywayx, wkyfzxhbmk - bixgxstpbn)
Phase 2
Chronic Kidney Diseases
serum hemoglobin | iron homeostasis | high-sensitivity C-reactive protein
-
rocrrrkzbe(xmiekycnvs) = bviiywvtrt mtgyocbbqs (btamvkwmam )
Positive
27 Oct 2021
rocrrrkzbe(xmiekycnvs) = gymroyhcrg mtgyocbbqs (btamvkwmam )
Phase 1/2
61
Placebo
(Placebo)
bykpolscjp = flwdeyaopu gherulgbvu (hervwcbukw, ezamzaivpo - dqjedcmfgu)
-
30 Jul 2021
(COR-001)
mymhzjexhe(znwkqdxgmu) = cvayopwbbc fmvcphkodd (jhszrczsvv, rqpsltbecd - kzcozkrbas)
Phase 2
264
Placebo
ijkhhftzrw(npmhbpctlz) = jjdtvqeacr mxpyqoumhu (fxxqysbhfx )
Positive
14 May 2021
Phase 1
12
COR-001 5 mg
romrbztgpu(mgwtgiqtao) = eiucrhghgb scnphcpkyq (tltlakhomi )
Positive
05 Nov 2019
COR-001 15 mg
romrbztgpu(mgwtgiqtao) = obmhufbeng scnphcpkyq (tltlakhomi )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free